Youngjoo Kwon | Anticancer Drug Development | Innovative Research Award

Published on | Editorial Board by World Top Scientists

Innovative Research Award

Youngjoo Kwon
Institution Ewha Womans University
Country South Korea
Scopus ID 12446435600
Documents 181
Citations 5,351
h-index 36
Subject Area Anticancer Drug Development
Event World Top Scientist Awards
ORCID 0000-0001-6256-3042

Youngjoo Kwon – Ewha Womans University

Youngjoo Kwon is a Professor at Ewha Womans University whose research focuses on anticancer drug discovery, molecular pharmacology, and medicinal chemistry. His published work includes studies on topoisomerase inhibitors, heat shock proteins, and targeted cancer therapeutics. The following profile summarizes his academic background and research contributions based on publicly available scholarly records.[1]

Abstract

Professor Youngjoo Kwon has contributed extensively to anticancer drug development through studies involving DNA topoisomerase inhibition, molecular signaling pathways, and therapeutic target discovery. His research integrates medicinal chemistry with pharmacological evaluation to identify novel compounds for cancer treatment. Numerous publications demonstrate sustained activity in translational biomedical research.[2]

Keywords

Anticancer drug development, medicinal chemistry, molecular pharmacology, DNA topoisomerase inhibitors, HSP27, targeted therapy, drug discovery, cancer biology.

Introduction

Youngjoo Kwon has established a research program centered on the discovery and optimization of therapeutic compounds for cancer treatment. His studies combine medicinal chemistry, molecular biology, and pharmacological evaluation to identify drug candidates with improved efficacy and selectivity. Research outcomes have been reported in internationally recognized peer-reviewed journals, demonstrating sustained contributions to anticancer drug development.[5]

Research Profile

Since joining Ewha Womans University, Youngjoo Kwon has led research in oncology-focused medicinal chemistry with emphasis on novel small-molecule therapeutics. His ORCID profile lists numerous peer-reviewed publications covering anticancer compounds, fibrosis research, and molecular pharmacology while collaborating with international researchers across multidisciplinary projects.[3]

Research Contributions

His research has contributed to the understanding of DNA topoisomerase inhibition, heat shock protein biology, tumor progression, fibrosis, and molecular mechanisms associated with therapeutic resistance. These investigations support the development of innovative treatment strategies and provide valuable knowledge for future translational and pharmaceutical research.[2]

Publications

Youngjoo Kwon has authored and co-authored research articles published in internationally recognized journals including European Journal of Medicinal Chemistry, EMBO Reports, Journal of Medicinal Chemistry, and Pharmaceuticals. His publications primarily investigate topoisomerase inhibitors, HSP27-targeted therapies, and innovative anticancer compounds using molecular and pharmacological approaches.[4]

Research Impact

The research profile reflects continuous scientific productivity through numerous peer-reviewed publications, collaborations, and contributions to medicinal chemistry. His work has supported advancements in targeted anticancer therapies while serving as an important reference for researchers investigating novel therapeutic compounds and molecular drug targets.[3]

Award Suitability

Based on publicly available scholarly information, Youngjoo Kwon demonstrates an extensive record of research activity in medicinal chemistry and anticancer drug development. His sustained publication history, collaborative research, and scientific contributions align with the evaluation criteria commonly considered for international academic recognition programs.[1]

Conclusion

Youngjoo Kwon continues to contribute to cancer pharmacology through innovative medicinal chemistry research and multidisciplinary collaborations. His scientific publications and ongoing investigations highlight a consistent commitment to developing new therapeutic approaches for complex diseases while advancing knowledge in pharmaceutical sciences.

References

  1. Seo, S. H., Hwang, S. Y., Hwang, S., Han, S., Park, H., Lee, Y. S., Rho, S. B., & Kwon, Y. (2022). Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R. EMBO Reports, 23.
    https://doi.org/10.15252/embr.202152977
  2. Hwang, S. Y., Shrestha, A., Park, S., Bist, G., Kunwar, S., Kadayat, T. M., Jang, H., Seo, M., Sheen, N., Kim, S., Lee, E. S., & Kwon, Y. (2022). Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors. European Journal of Medicinal Chemistry, 227, 113916.
    https://doi.org/10.1016/j.ejmech.2021.113916
  3. Jeon, K. H., Park, S., Jang, H. J., Hwang, S. Y., Shrestha, A., Lee, E. S., & Kwon, Y. (2021). AK-I-190, a new catalytic inhibitor of Topoisomerase II with anti-proliferative and pro-apoptotic activity on androgen-negative prostate cancer cells. International Journal of Molecular Sciences, 22(20), 11246.
    https://doi.org/10.3390/ijms222011246
  4. Yim, J., Lim, H. H., & Kwon, Y. (2021). COVID-19 and pulmonary fibrosis: Therapeutics in clinical trials, repurposing, and potential development. Archives of Pharmacal Research, 44, 499-513.
    https://doi.org/10.1007/s12272-021-01331-9
  5. Kadayat, T. M., Park, S., Shrestha, A., Jo, H., Hwang, S. Y., Katila, P., Shrestha, R., Nepal, M. R., Noh, K., Kim, S. K., Lee, E. S., & Kwon, Y. (2019). Discovery and biological evaluations of halogenated 2,4-diphenyl indeno[1,2-b]pyridinol derivatives as potent Topoisomerase IIΞ±-targeted chemotherapeutic agents for breast cancer. Journal of Medicinal Chemistry, 62(19), 9195-9213.
    https://doi.org/10.1021/acs.jmedchem.9b00970

Sara Franzi | Biology Transplantology | Women Researcher Award

Published on | Editorial Board by World Top Scientists

Dr. Sara Franzi | Biology Transplantology | Women Researcher Award

Researcher | Policlinico of Milan | Italy

Dr. Sara Franzi is a Researcher at the IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan, specializing in transplantation biology and biomedical research. She holds advanced academic training in life sciences, with a strong foundation in molecular and cellular biology. Her professional trajectory includes postdoctoral fellowships and research appointments at leading Italian IRCCS institutes, where she has contributed to multidisciplinary projects in thoracic surgery, lung transplantation, neuroimmunology, and neuromuscular diseases. Her work spans experimental and translational research, including studies on TGF-beta signaling in myopathies, genetic determinants of drug response in myasthenia gravis, and immune-mediated neurological disorders. She has demonstrated leadership in coordinating research initiatives and contributes to scientific dissemination as a medical writer and reviewer for peer-reviewed journals. Dr. Franzi’s research output includes publications in reputable journals, reflecting her commitment to advancing knowledge in transplantation and disease mechanisms. Her professional affiliations, editorial contributions, and continued engagement in high-impact research underscore her recognition within the scientific community.

Citation Metrics (Google Scholar)

392
300
200
100
0

392

11

10

Citations

Documents

h-index


Top 5 Featured Publications

 

Judita Kinkorova | Biobanking | Best Researcher AwardΒ 

Published on | Editorial Board by World Top Scientists

Assoc. Prof. Dr. Judita Kinkorova | Biobanking | Best Researcher AwardΒ 

Senior Scientist | University Hospital in Pilsen | Czech Republic

Assoc. Prof. Dr. Judita KinkorovΓ‘ is a leading researcher in biobanking, personalized medicine, and preventive healthcare, recognized for her significant contributions to international research collaboration. She has successfully coordinated major European research initiatives, including FP7 and Horizon 2020 projects, and has played a pivotal role in developing hospital-integrated biobanks that strengthen biomedical research infrastructure. Her active participation in scientific societies and editorial boards reflects her influence and thought leadership in advancing precision health. Dr. KinkorovÑ’s work integrates scientific rigor with strategic collaboration, mentorship, and policy engagement, demonstrating strong potential for further innovation in genomic and biomarker research, sustainable biobanking, and cross-border scientific partnerships. Her research output is substantial, comprising 47 Scopus-indexed publications, cited 852 times by 744 documents, with an h-index of 12, highlighting the measurable impact and quality of her contributions to the field.

Profile: Scopus | ORCID

Featured Publications

1. J. KinkorovΓ‘ and O. Topolčan, “Biobanks in the era of big data: objectives, challenges, perspectives, and innovations for predictive, preventive, and personalised medicine,” EPMA Journal, 2020.

2. J. KinkorovΓ‘, O. Topolčan, and R. Kučera, “Informed Consent in the Newly Established Biobank,” International Journal of Environmental Research and Public Health, 2019.

3. J. KinkorovΓ‘ and O. Topolčan, “Biobanks in Horizon 2020: sustainability and attractive perspectives,” EPMA Journal, 2018.

4. “The 44th Congress of the International Society of Oncology and Biomarkers: Rio de Janeiro, Brazil, 7-10 September 2017,” Future Medicine, 2018.

5. J. KinkorovΓ‘ and O. Topolčan, “Biobanks – European infrastructur | Biobanky – EvropskΓ‘ infrastruktura,” Casopis Lekaru Ceskych, 2016.

Laura Garriga-Grimau | Medicine and Dentistry | Best Researcher Award

Published on | Editorial Board by World Top Scientists

Dr. Laura Garriga-Grimau | Medicine and Dentistry | Best Researcher Award

Physician at Hospital Universitari Vall d’Hebron, Spain

Dr. Laura Garriga-Grimau is a dedicated pediatric pulmonologist based at Vall d’Hebron University Hospital in Barcelona, Spain. She specializes in bronchiectasis, cystic fibrosis, and other chronic pediatric lung conditions. Her work bridges clinical practice, academic research, and teaching. She is actively involved in multiple international research collaborations, including the European Respiratory Society (ERS) and the Child-BEAR-Net Registry. A strong advocate for improving respiratory care in children, Dr. Garriga-Grimau has authored numerous peer-reviewed publications and contributed to global studies shaping pediatric lung health guidelines. Her academic and clinical background is enriched by international clinical training in Australia and active teaching roles at the Autonomous University of Barcelona. Known for her collaborative leadership and deep scientific insight, she continues to contribute to innovation in pediatric respiratory medicine while mentoring future healthcare professionals. Her work is both evidence-driven and patient-centered, earning her a growing reputation in European and global pediatric research communities.

πŸ”ΉΒ Professional ProfileΒ 

Scopus Profile
ORCID ProfileΒ 

πŸ†Strengths for the Award

Dr. Laura Garriga-Grimau has demonstrated a strong commitment to advancing pediatric respiratory medicine through a blend of clinical excellence, academic research, and international collaboration. Her specialization in bronchiectasis and cystic fibrosis has positioned her as a key contributor in areas that are often underrepresented in pediatric research. She currently holds leadership roles in prominent research initiatives, such as Chair of the ERS Task Force on Transitioning Adolescents with Bronchiectasis, and Deputy Co-Chair of the Child-BEAR-Net Registry, reflecting the recognition she commands within global respiratory research communities. These roles not only highlight her scientific insight but also her ability to coordinate multinational teams and influence clinical policy development.

Her publication record is both prolific and impactful, including research in The Lancet Respiratory Medicine, New England Journal of Medicine, and other peer-reviewed international journals. Dr. Garriga-Grimau has contributed to high-quality, multi-center studies and registries that address real-world challenges in diagnosis, treatment, and care models for pediatric lung diseases. Notably, her involvement in the SHIP-CT trial and the Spanish Pediatric Bronchiectasis Registry demonstrates her ability to participate in and lead complex clinical research initiatives with both academic and translational value. Her research outputs are data-driven, well-cited, and directly relevant to improving health outcomes in children globally.

In addition to her research achievements, Dr. Garriga-Grimau has actively bridged the gap between academia and clinical practice. She contributes as a faculty member in the Pediatric Pulmonology Master’s program at the Autonomous University of Barcelona and has been involved in mentoring and training future clinicians and researchers. Her international clinical exposure, including a bronchiectasis fellowship in Australia, enhances the global relevance and cultural sensitivity of her work. This combination of academic productivity, clinical innovation, and leadership in international research networks makes her a well-rounded and highly deserving candidate for the Best Researcher Award.

πŸŽ“Education

Dr. Laura Garriga-Grimau completed her medical education and pediatric residency through the Spanish MIR system at the University of Barcelona, one of Spain’s leading academic medical centers. Following her pediatric training, she pursued specialized academic advancement through a Master’s degree in Pediatric Pulmonology from the Autonomous University of Barcelona (UAB), where she later became a faculty member. Her passion for research and respiratory medicine led her to complete a PhD focused on cystic fibrosis at Vall d’Hebron University Hospital, contributing significant findings to the field. In addition to her formal education, Dr. Garriga-Grimau enriched her academic and clinical knowledge with a training fellowship in bronchiectasis at the Queensland Children’s Hospital in Australia. Her continuous pursuit of learning, from clinical practice to translational research, has equipped her with a strong foundation in evidence-based medicine and multidisciplinary collaboration, shaping her into a leader in pediatric respiratory care both in Spain and internationally.

πŸ’ΌΒ Experience

Dr. Laura Garriga-Grimau has built an extensive and dynamic professional career in pediatric pulmonology, anchored at Vall d’Hebron University Hospital. She serves as a consultant in the Pediatric Pulmonology Department, where she treats complex respiratory conditions, including cystic fibrosis and bronchiectasis. Her clinical experience is complemented by her academic involvement as a lecturer in the Pediatric Pulmonology Master’s program at the Autonomous University of Barcelona. She completed international clinical training in Australia, focusing on bronchiectasis, and collaborates with research networks such as the ERS, ERN-Lung, and Child-BEAR-Net. Her career integrates hands-on patient care with data-driven research, highlighting her ability to translate science into practice. In leadership roles such as Chair of the ERS Task Force on adolescent bronchiectasis transition and Deputy Co-Chair of Child-BEAR-Net, she coordinates multinational teams and projects. Her balanced experience across clinical, research, and educational domains establishes her as a well-rounded and forward-thinking physician-scientist.

πŸ†Β Awards and Honors

While specific individual awards are not listed in her profile, Dr. Laura Garriga-Grimau’s numerous prestigious roles and peer-reviewed publications serve as strong indicators of her academic and professional recognition. She has earned notable leadership positions in internationally recognized research bodies such as the European Respiratory Society (ERS) and the Child-BEAR-Net network, which are typically awarded based on merit, contribution, and peer endorsement. She is a key author and collaborator in top-tier journals including The Lancet Respiratory Medicine and The New England Journal of Medicineβ€”an honor in itself that reflects a high level of expertise and scientific impact. Her inclusion in global studies and research registries, as well as her involvement in shaping clinical guidelines, affirms her reputation in the field of pediatric pulmonology. Furthermore, her appointment as faculty at a major academic institution and her PhD achievements represent high academic recognition within both national and international medical communities.

πŸ”¬Research Focus on Medicine and Dentistry

Dr. Garriga-Grimau’s research centers on pediatric bronchiectasis, cystic fibrosis, and related respiratory disorders, with an emphasis on improving diagnostics, treatment protocols, and health equity in chronic pediatric lung care. She is actively involved in several major international studies and registries, including the Child-BEAR-Net Registry and SHIP-CT trial. Her research evaluates multicountry clinical variations, healthcare transitions from adolescence to adulthood, and therapy optimization for children with chronic respiratory disease. She collaborates on translational studies that influence clinical guidelines and promote standardized care across different healthcare systems. Her work particularly emphasizes underserved populations, including Indigenous communities, reflecting her commitment to inclusive, global health research. By integrating clinical experience with robust epidemiological and translational approaches, Dr. Garriga-Grimau’s research not only advances scientific understanding but also directly enhances patient outcomes. She contributes to major publications and plays key roles in shaping pediatric pulmonology’s research priorities at the European and global level.

πŸ“šΒ Publications Top Notes

  • First results from the international paediatric bronchiectasis registry (Child‑BEAR‑Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cross‑sectional study

    • Authors: Laura Garriga‑Grimau; Ahmad Kantar; Keith Grimwood; Charl Verwey; Refiloe Masekela; Diane Gray; Ameena Goga; Bulent Karadag; Ela Erdem Eralp; Yasemin Gokdemir; et al.

    • Year: 2025

    • Citations: 1 (as per Scopus/ResearchGate)

  • Guiding practice principles for clinicians who work with Indigenous people

    • Authors: AndrΓ© Schultz; Anneβ€―B. Chang; Donnaβ€―M. Mason; Julieβ€―M. Marchant; Lesleyβ€―A. Versteegh; Mareeβ€―Toombs; Laura Garriga‑Grimau; CRE Extended Group

    • Year: 2025

  • Bronchiectasis in pediatrics

    • Authors: Laura Garriga‑Grimau; Eva Polverino; Antonio Moreno‑GaldΓ³

    • Year: 2025

  • Implementation of the Spanish Paediatric Bronchiectasis Registry (Child‑BEAR‑es Registry)

    • Authors: Laura Garriga‑Grimau; VerΓ³nica Sanz‑Santiago; Antonio Moreno‑GaldΓ³

    • Year: 2024

  • Improving the Diagnosis and Treatment of Paediatric Bronchiectasis Through Research and Translation

    • Authors: Anne B. Chang; Shyamali C. Dharmage; Julie M. Marchant; Gabrielle B. McCallum; Peter S. Morris; Andre Schultz; Maree Toombs; Danielle F. Wurzel; Stephanie T. Yerkovich; Keith Grimwood; Laura Garriga‑Grimau; CRE extended group

    • Year: 2024

  • Asma (book chapter)

    • Author: Laura Garriga‑Grimau

    • Year: 2022

  • PneumΓ²nia per Streptococcus pyogenes a l’edat pediΓ trica

    • Author: Laura Garriga‑Grimau

    • Year: 2022

  • The effect of inhaled hypertonic saline on lung structure in children aged 3–6β€―years with cystic fibrosis (SHIP‑CT)

    • Authors: Harm A.W.M. Tiddens; Yuxin Chen; Eleni‑Rosalina Andrinopoulou; et al., including Laura Garriga‑Grimau

    • Year: 2022

  • Triple Therapy for Cystic Fibrosis Phe508del‑Gating and ‑Residual Function Genotypes

    • Authors: Peter J. Barry; Marcus A. Mall; Antonio Álvarez; et al., including Laura Garriga‑Grimau

    • Year: 2021

  • How abnormal is the normal? Clinical characteristics of CF patients with normal FEV₁

    • Authors: Malena Cohen‑Cymberknoh; Elad Ben Meir; Silvia Gartner; et al., including Laura Garriga‑Grimau

    • Year: 2021

  • Earlier clinical case reports (2012–2015)

    • Authors: Laura Garriga‑Grimau et al.

    • Years: 2012–2015

πŸ“ŒΒ Conclusion

Dr. Laura Garriga-Grimau exemplifies the rare combination of clinical expertise, academic leadership, and collaborative spirit essential for advancing global pediatric pulmonology. Her commitment to research excellence, her leadership in multinational registries and task forces, and her drive to improve outcomes for children with chronic respiratory diseases mark her as an innovator in the field. Whether through her patient care, her mentorship of future specialists, or her groundbreaking studies in bronchiectasis and cystic fibrosis, Dr. Garriga-Grimau continues to push the boundaries of pediatric respiratory medicine. Her contributions resonate not only within academic journals but also in real-world clinical settings across borders. As she builds on her already distinguished career, she remains a key force in shaping the future of respiratory healthcare for children worldwide. Dr. Garriga-Grimau is undoubtedly a deserving candidate for any accolade recognizing research excellence, innovation, and global impact in medicine.

Dr. Laura Cerchia | translational cancer research | Best Researcher Award

Published on | Editorial Board by World Top Scientists

Dr. Laura Cerchia | translational cancer research | Best Researcher Award

PI, Group Leader at Institute of Endotypes in Oncology, Metabolism and Immunology β€œG. Salvatore”, National Research Council, Italy

Dr. Laura Cerchia is a leading researcher in cancer-targeting RNA aptamer technologies, serving as Group Leader at the Institute of Endotypes in Oncology, Metabolism and Immunology (CNR, Italy). She pioneered the cell-SELEX method, widely adopted across international labs, and developed multiple aptamers targeting tumor biomarkers such as EGFR, AXL, and PDGFRΞ². These aptamers have significant applications in imaging, immunotherapy, and targeted drug delivery, with some now used globally in advanced nanomedicine platforms. Author of over 90 peer-reviewed publications with an H-index of 36, she also holds four international patents. Dr. Cerchia has received numerous grants and serves on several national and international scientific committees, including Horizon Europe’s PHIRE project. Her expertise is recognized through roles as evaluator, editorial board member, and scientific advisor. Her work bridges fundamental research and therapeutic innovation, making her a key figure in translational oncology and a strong candidate for the Best Researcher Award.

Professional ProfileΒ 

Scopus Profile
ORCID ProfileΒ 

Education

Dr. Laura Cerchia earned her PhD in Biochemical Sciences, building a strong academic foundation in molecular biology and biochemistry. Her educational background equipped her with expertise in RNA biology, molecular diagnostics, and therapeutic development. Her advanced training allowed her to explore the structural and functional aspects of nucleic acids, which later became central to her innovative work in aptamer development. During her academic years, she developed an early interest in translational research, which led her to specialize in the design of synthetic oligonucleotides for medical applications. Her doctoral and postdoctoral studies laid the groundwork for her pioneering approach in using aptamers for targeted cancer therapy. Her education not only deepened her scientific knowledge but also instilled a critical problem-solving mindset that continues to influence her research directions. Her scholarly path reflects a combination of academic rigor and innovative thinking, forming the basis for her future contributions to biomedical science.

Professional Experience

Dr. Laura Cerchia is currently Group Leader at the Institute of Endotypes in Oncology, Metabolism and Immunology β€œG. Salvatore” (IEOMI) within the National Research Council of Italy (CNR). Her professional journey has been marked by impactful roles in both scientific leadership and collaborative research. She developed the widely used cell-SELEX procedure and generated several clinically relevant RNA aptamers targeting key tumor markers. Beyond laboratory research, Dr. Cerchia serves on editorial boards of journals such as Scientific Reports and Molecules, and holds evaluative and advisory roles in national and international research bodies, including the Horizon Europe-funded PHIRE project. Her career reflects a balance of scientific innovation, project management, and institutional leadership. She has successfully secured multiple research grants, built interdisciplinary teams, and advanced new diagnostic and therapeutic approaches. Her professional experience showcases her ability to lead complex research initiatives and influence the broader scientific and clinical communities.

Research Interest

Dr. Cerchia’s research focuses on the development of nuclease-resistant RNA aptamers for cancer theranostics, therapeutics, and targeted drug delivery. She is especially interested in the use of aptamers as precision tools for recognizing and binding specific biomarkers in tumors, such as EGFR, AXL, and PDGFRΞ². Her work involves designing aptamers that can be used for in vitro and in vivo imaging, antagonistic therapies, and as carriers for chemotherapeutics, small molecule inhibitors, siRNAs, or photosensitizers. Her innovations in cell-SELEX have enabled the selection of highly specific aptamers against aggressive cancer types like glioblastoma, NSCLC, and triple-negative breast cancer (TNBC). She is also exploring the potential of aptamers in immunotherapy, including their integration with nanomedicine platforms. Her interest lies in translating basic molecular discoveries into clinical applications, with a strong focus on personalized medicine. Overall, her research aims to bridge gaps between molecular biology, oncology, and therapeutic delivery systems.

Award and Honor

Dr. Laura Cerchia has received multiple national and international recognitions for her contributions to cancer research and aptamer technology. She is the recipient of prestigious research grants and has been invited to serve on scientific evaluation panels, including for the Wellcome Trust (UK), ANR SHAMS, PRIN, and Horizon Europe projects. In 2018, she achieved the National Scientific Qualification, allowing her to function as a Full Professor in general and clinical pathology within Italian universitiesβ€”an acknowledgment of her academic and professional excellence. She also serves as President and expert evaluator for PRIN 2022 PNRR – ERC Sector LS1, reinforcing her leadership role in shaping national research priorities. Her aptamers are cited and utilized worldwide, further validating the high translational value of her work. In addition to her editorial board positions, these honors demonstrate her broad influence, scientific credibility, and sustained contributions to advancing biomedical research on both national and international levels.

Conclusion

Dr. Laura Cerchia exemplifies the qualities of a world-class biomedical researcher through her pioneering work in RNA aptamer technologies, extensive publication record, and active leadership in the international scientific community. With a robust educational background, decades of impactful professional experience, and deep research expertise, she has made significant contributions to translational cancer therapy. Her innovations have enabled more precise targeting of tumors, enhancing both diagnostic and therapeutic capabilities. Her work has not only influenced academic circles but also spurred technological advances in nanomedicine and drug delivery. The widespread adoption of her aptamers across global research groups attests to the relevance and utility of her discoveries. Coupled with numerous awards, advisory roles, and editorial contributions, her profile reflects excellence, leadership, and a forward-looking vision in biomedical science. Dr. Cerchia’s continued efforts make her a strong candidate for high honors such as the Best Researcher Award and a role model in scientific innovation.

Publications Top Notes

  • Title: A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signaling
    Authors: Not listed
    Year: 2025

  • Title: A novel CD44-targeting aptamer recognizes chemoresistant mesenchymal stem-like TNBC cells and inhibits tumor growth
    Authors: Not listed
    Year: 2025

  • Title: Preclinical Toxicological Characterization of Porphyrin-Doped Conjugated Polymer Nanoparticles for Photodynamic Therapy
    Authors: Not listed
    Year: 2025

  • Title: Urine-Stable Aptamer-Conjugated Gold Nanorods for the Early Detection of High-Grade Bladder Cancer Residual Disease
    Authors: Not listed
    Year: 2025
    Citations: 1

  • Title: Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies
    Authors: Not listed
    Year: 2024
    Citations: 11

  • Title: Ferroptosis in Cancer: Epigenetic Control and Therapeutic Opportunities
    Authors: Not listed
    Year: Not available
    Citations: 6

  • Title: Subtype Transdifferentiation in Human Cancer: The Power of Tissue Plasticity in Tumor Progression
    Authors: Not listed
    Year: Not available
    Citations: 2

  • Title: Correction to: Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids
    Authors: Not listed
    Year: 2024

  • Title: Correction to: Selective Photo-Assisted Eradication of Triple-Negative Breast Cancer Cells through Aptamer Decoration of Doped Conjugated Polymer Nanoparticles
    Authors: Not listed
    Year: 2022
    Citations: 1

Olga Moskalenko | Medicine | Best Researcher Award

Published on | Editorial Board by World Top Scientists

Assoc Prof Dr. Olga Moskalenko | Medicine | Best Researcher Award

Candidate of Biological Sciences, Russia

Olga Leonidovna Moskalenko is a dedicated educator and researcher in the fields of pediatrics, psychology, and medical education. With extensive training in various medical and pedagogical disciplines, she has established herself as a prominent figure in her field. 🌟

Publication Profile

Scopus

Education

Olga graduated from the Krasnoyarsk State Medical Academy in 2005, specializing in Pediatrics. She has pursued multiple advanced training programs in Medical Informatics, Pedagogical Education, and Psychology, further enriching her knowledge and skills. πŸŽ“

Experience

She currently serves as an Associate Professor at the Krasnoyarsk State Medical University, where she contributes to the Department of Histology, Cytology, and Embryology. Additionally, she holds the position of Senior Researcher at the Research Institute of Medical Problems of the North, showcasing her commitment to advancing medical research and education. πŸ₯

Research Interests

Olga’s research focuses on critical topics such as internet addiction in adolescents, psychological interviewing, and pathophysiology. Her work aims to address significant psychological and health issues impacting young people today. πŸ”¬

Awards

Throughout her career, Olga has led numerous scientific projects and received grants for her research on internet addiction and cancer diagnostics, reflecting her dedication to improving health outcomes in her community. πŸ†

Publications

Griffiths, M. D., & Moskalenko, O. L. (2024). Title of the Publication. Journal Name.

Moskalenko, O. L. (2021). Title of the Publication. Journal Name.

Moskalenko, O. L. (2020). Title of the Publication. Journal Name.

 

Mario Flores | Computational Biology | Next-Generation Science Trailblazer Award

Published on | Editorial Board by World Top Scientists

Assist Prof Dr. Mario Flores | Computational Biology | Next-Generation Science Trailblazer Award

Biomedical, University of Texas at San Antonio, United States

Profile

Google Scholar

Short Bio

Dr. Mario A. Flores is an Assistant Professor at the University of Texas at San Antonio, specializing in artificial intelligence models for disease phenotype predictions, biomarker identification, and explainable mechanisms. His innovative research integrates various AI techniques to enhance our understanding of disease progression, particularly in oncology.

Education

Dr. Flores holds a Bachelor’s degree in Electronics Engineering from the Metropolitan Autonomous University, a Master’s in Applied Mathematics, and a PhD in Electrical Engineering (Computational Biology) from the University of Texas at San Antonio. He completed his postdoctoral fellowship at the National Center for Biotechnology Information (NCBI), NIH.

Experience

Since 2020, Dr. Flores has served as an Assistant Professor with joint appointments in Electrical and Computer Engineering (ECE) and Biomedical Engineering (BME) at UTSA. His prior roles include NIH Postdoctoral Fellow at NCBI and Research Associate at the Greehey Children’s Cancer Research Institute, showcasing his extensive experience in computational biology and bioinformatics.

Research Interests

Dr. Flores’s research focuses on developing AI tools for disease gene dependence prediction, utilizing spatially resolved transcriptomics, single-cell RNA sequencing, and Electronic Health Records (EHRs) to analyze tumor microenvironments. His work aims to bridge gaps in understanding disease mechanisms and improve patient outcomes through precision medicine.

Awards

Dr. Flores has received numerous awards for his research, including funding from the NIH for projects on neural circuits inhibiting pain, and recognition from the AIM-AHEAD Fellowship program, supporting his efforts to address health disparities in minority populations.

Publications Top Notes

Dr. Flores has authored several impactful publications, including:

New tools for spatial biology transcriptomics & proteomics in immuno-oncology, Immuno-Oncology Insights, 2023.

Deep learning tackles single-cell analysisβ€”a survey of deep learning for scRNA-seq analysis, Brief in Bioinformatics, 2022.

Transformer for Gene Expression Modeling (T-GEM): An Interpretable Deep Learning Model for Gene Expression-Based Phenotype Predictions, Cancers, 2022.

 

Mohamed Ahmed | Quality- medicine | Best Research Article Award

Published on | Editorial Board by World Top Scientists

Assist Prof Dr. Mohamed Ahmed | Quality- medicine | Best Research Article Award

Chair of qualit unit, College of engineering- KSU, Saudi Arabia

Dr. Mohamed Abdel Fattah Ahmed – Short Biography
πŸ§‘β€πŸ« Dr. Mohamed Abdel Fattah Ahmed is a dedicated academic professional with an extensive career in engineering education. He currently serves as an Assistant Professor at King Saud University, College of Engineering, in Riyadh, Saudi Arabia, a position he has held since 1993. His earlier academic roles include teaching at Assiut University, Egypt, and part-time at Banah Higher Technological Institute. With over four decades of experience, Dr. Ahmed has made significant contributions to industrial engineering and mechanical engineering, specializing in quality management, decision-making, and project management. His broad expertise encompasses cost estimation, workshop design, and spare parts control.

Profile

Scopus

Strengths for the Award

Dr. Mohamed Abdel Fattah Ahmed demonstrates a robust academic and research background with a significant focus on engineering fields, particularly industrial and mechanical engineering. His extensive education, including a Ph.D. in Industrial Engineering from Japan, along with practical training in Total Quality Management (TQM), highlights his technical proficiency. The most notable strength is his recent contributions to the journal Mechanics of Advanced Materials and Structures in 2023. His research topics, including nonlinear continuum thermo-mechanics, advanced building materials, and artificial intelligence applications in engineering, show innovation, relevance, and interdisciplinary scope. These subjects are highly applicable to modern challenges in materials science, engineering, and artificial intelligence, marking his work as impactful and forward-thinking.

Areas for Improvement

While Dr. Mohamed’s research addresses contemporary issues, the language barrier might pose challenges, especially when writing and communicating complex ideas in English. His proficiency is described as “fair enough,” which may limit the clarity and accessibility of his publications. Additionally, while his research shows a high degree of specialization, expanding the practical applications of his findings or engaging in more collaborative, international research efforts could elevate his work’s influence and reach. Moreover, enhancing the focus on direct real-world implications, such as environmental or societal benefits, would strengthen the potential for wider recognition and impact in multidisciplinary contexts.

Education

πŸŽ“ Dr. Ahmed holds a Ph.D. in Industrial Engineering from Chubu University, Japan (1989), where he focused on quality engineering and service parts control. He also earned an M.Sc. in Mechanical Engineering from Assiut University, Egypt (1982), and a B.Sc. in Production Engineering from Alexandria University, Egypt (1976). Additionally, he holds a Diploma in Total Quality Management (TQM) from Kyoto University, Japan (1985). His further qualifications include certified Six Sigma Master Black Belt and PMP certification from PMI-USA.

Experience

πŸ”§ Throughout his career, Dr. Ahmed has held various academic and professional positions, starting as a Teaching Assistant at Assiut University (1978-1983) and later as an Assistant Professor at the same institution (1990-1993). His long-standing tenure at King Saud University has allowed him to impart knowledge in industrial and production engineering, and he has been actively involved in various administrative and research roles. He is also an accredited Quality Management System Auditor (ISO 9001:2015).

Research Interests

🧠 Dr. Ahmed’s research interests span across several domains, including engineering management education, cost estimation, academic accreditation, decision-making processes, and quality management. He is particularly passionate about project management, workshop design, and spare parts control. His research contributes significantly to improving management systems and industrial processes.

Awards

πŸ† Dr. Ahmed has received several certifications and professional recognitions, including being a Six Sigma Certified Master Black Belt (Integral-USA) and an IRCA Certified Quality Management System Auditor (ISO 9001:2015). His contributions to the academic and professional fields of engineering management have earned him respect and accolades throughout his career.

Publications Top Notes

πŸ“š Dr. Ahmed has an impressive list of research publications, contributing to significant advancements in engineering and applied sciences. Below are some of his recent works:

“Robust Framework for Severity Detection of Knee Osteoarthritis Using an Efficient Deep Learning Model”, International Journal of Pattern Recognition and Artificial Intelligence, 2023. DOI: 10.1142/S0218001423520109

“Multi-Agent Variational Approach for Robotics: A Bio-Inspired Perspective”, Biomimetics, 2023. DOI: 10.3390/biomimetics8030294

“A Novel Evolving Framework for Energy Management in Combined Heat and Electricity Systems with Demand Response Programs”, Sustainability, 2023. DOI: 10.3390/su151310481

“Forced Vibration Analysis of the Axially Reinforced Thick Concrete Plate Using General Expression of the Polynomial Series Theory: Development and Validation of a Deep Neural Network”, Materials Today Communications, 2023. DOI: 10.1016/j.mtcomm.2023.106419

“Nonlinear Continuum Thermo-Mechanics of the Composite Thick Panel Used in Concrete Ceilings via General Expression of the Polynomial Series Theory”, Mechanics of Advanced Materials and Structures, 2023. DOI: 10.1080/15376494.2023.2218367

“Soft Computational Approach on the Thermoelastic Assessment of Sandwich Beams with Transversely Functionally Graded Composite Concrete Face-Sheets as an Advanced Building Material”, Mechanics of Advanced Materials and Structures, 2023. DOI: 10.1080/15376494.2023.2227413

Conclusion

Dr. Mohamed Abdel Fattah Ahmed is a strong candidate for the “Best Research Article Award” due to his substantial contributions to engineering and materials science. His innovative research in advanced materials, thermo-mechanics, and the integration of artificial intelligence aligns well with current global trends. However, improvement in communication skills and broader collaboration would further enhance the recognition of his work. Overall, his depth of knowledge and recent impactful publications make him a compelling contender for the award.

Samer Younes | Pharmacology | Best Researcher Award

Published on | Editorial Board by World Top Scientists

Dr. Samer Younes | Pharmacology | Best Researcher Award

Department of Pharmacy, Tartous University, Syria

🌟 Samer Younes is a dedicated and forward-thinking pharmacy graduate from Tartous University, Syria. With a strong academic background and diverse experience in both practical pharmacy and research, Samer is committed to continuous learning and professional development. His work ethic is demonstrated through his active participation in community volunteering, internships, and a keen interest in expanding his expertise in the field of pharmacy and nutrition.

Profile

Google Scholar

Research for “Best Researcher Award”

Strengths for the Award

1. Strong Academic Foundation and Practical Experience:
Samer Younes has demonstrated a solid academic foundation with a Bachelor’s degree in Pharmacy from Tartous University, complemented by practical experience in various pharmacy roles and internships. His work as a pharmacist involved crucial tasks such as prescription processing and handling patient queries, showcasing his applied knowledge in the field.

2. Commitment to Continuous Learning and Professional Development:
Samer’s commitment to professional growth is evident from his various certifications, including Quality Advisor and specialized training in Nutrition and Laboratory Work. These certifications not only add to his qualifications but also highlight his proactive approach to expanding his skill set and knowledge.

3. Volunteer Experience and Community Engagement:
His volunteer work with UNICEF and involvement in the Campaign against Covid-19 underline his dedication to societal well-being and public health. His role in these initiatives, including vaccinations and monitoring children’s rights, demonstrates his ability to apply his expertise in real-world scenarios and contribute to community health.

4. Language and Digital Skills:
Samer possesses proficiency in multiple languages, which enhances his ability to communicate and collaborate in diverse settings. His digital skills, including expertise in Microsoft Office and analytical tools, are essential for modern research and data analysis.

5. Strong Recommendations:
Samer has received commendations from reputable professors, such as Wissam Zam and Zeina Hamama, who can vouch for his academic prowess and research capabilities. Their recommendations add credibility to his achievements and potential as a researcher.

Areas for Improvement

1. Limited Research Publications:
While Samer has a commendable academic background and practical experience, his publication record appears limited. Expanding his research output and publishing in high-impact journals could enhance his visibility and influence in the field of pharmacy and research.

2. Focused Research Experience:
Although Samer has engaged in diverse roles and projects, a more focused research experience in specific areas of pharmacy or a related field could strengthen his application. Specializing in a niche area and contributing significant research could further solidify his candidacy for the award.

3. Networking and Collaboration:
Building a stronger professional network and engaging in collaborative research projects could provide additional opportunities for growth and recognition. Participating in conferences and research forums would also help him gain further exposure and feedback from the scientific community.

4. Enhanced Research Visibility:
Increasing his presence in research communities, such as ResearchGate and Google Scholar, by regularly updating his profiles and engaging with other researchers could improve his visibility and impact in the research domain.

Education

πŸŽ“ Bachelor Degree in Pharmacy
Department of Pharmacy, Tartous University
(01/09/2018 – 31/01/2024)
Samer graduated with a final grade of 72.2/100, having gained a solid foundation in pharmaceutical sciences and practical experience through his coursework and projects.

Experience

πŸ’Š Pharmacist
Ghadeer Pharmacy
(01/12/2020 – 19/08/2022)
Samer managed prescription processing, handled patient queries, ensured compliance with pharmacy regulations, and updated inventory information, showcasing his practical expertise in the pharmaceutical field.

πŸ”¬ Internship: Campaign Against Covid-19
(12/09/2020 – 12/05/2021)
In this role, Samer contributed to examinations and vaccinations, playing a crucial part in the fight against the pandemic.

🌍 Volunteering: UNICEF
(18/11/2013 – 20/11/2013)
Samer’s work with UNICEF included training and voluntary activities, reflecting his commitment to global health and community support.

Research Interests

Samer’s research interests lie in the intersection of nutrition and pharmacology, particularly focusing on the impact of micronutrients on health conditions and treatment outcomes. His work aims to advance understanding in these areas and contribute to more effective therapeutic strategies.

Awards and Certifications

  • Quality Advisor – Insight (Training Development & Consulting) (24/11/2022 – 28/11/2022)
  • Laboratory Work Level 1+2 – Insight (24/11/2022 – 28/11/2022)
  • Nutrition and Diets – Insight (02/02/2022 – 20/02/2022)
  • Nutrition Basics – Insight (12/12/2021 – 20/12/2021)

Publications Top Notes

  1. The Role of Nutrition on the Treatment of Covid-19
    Human Nutrition & Metabolism, 200255 (2024)
    Cited by: 4
  2. The Role of Micronutrients on the Treatment of Diabetes
    Human Nutrition & Metabolism, 200238 (2024)
    Cited by: 4
  3. The Impact of Micronutrients on the Sense of Taste
    Human Nutrition & Metabolism, 200231 (2023)
    Cited by: 2
  4. The Relationship Between Gender and Pharmacology
    Current Research in Pharmacology and Drug Discovery, 100192 (2024)
    Cited by: 1

Conclusion

Samer Younes exhibits many strengths that align well with the criteria for the “Best Researcher Award.” His academic qualifications, practical experience, and dedication to continuous learning and community service are commendable. To strengthen his candidacy, focusing on increasing his research publications, specializing in a specific area, and enhancing his professional network and visibility will be crucial. With his solid foundation and commitment to growth, Samer has the potential to make significant contributions to the field and be a strong contender for the award.

 

Vuanghao Lim | Pharmaceutical Science | Best Researcher Award

Published on | Editorial Board by World Top Scientists

Assoc Prof Dr. Vuanghao Lim | Pharmaceutical Science | Best Researcher Award

University Lecturer, USM, Malaysia

πŸ‘¨β€πŸ”¬ Lim Vuanghao is an Associate Professor at the Advanced Medical and Dental Institute, Universiti Sains Malaysia (USM). His extensive work in nanodrug delivery and green nano-synthesis has made him a recognized figure in the fields of pharmaceutical technology and metabolomics. He has held various leadership roles, including Head of the Integrative Medicine Cluster at USM. Lim’s research focuses on cutting-edge therapeutic strategies, emphasizing targeted drug delivery and the application of metabolomics in medical sciences.

Profile

Google Scholar

Strengths for the Award

Extensive Research Experience: Dr. Lim Vuanghao has a rich background in nanodrug delivery, green nano-synthesis, and metabolomics/chemometrics. His research contributions are well-documented across multiple platforms, including Web of Science, ORCID, Scopus, and Google Scholar.

Diverse Educational Background: Dr. Lim’s academic qualifications are impressive, with a Ph.D. in Pharmaceutical Technology, an M.Sc. in Pharmacy, a B.Sc. in Chemical Sciences, and additional qualifications in Acupuncture and Energy Medicine. This multidisciplinary education underpins his innovative research in nanotechnology and drug delivery systems.

Successful Grant Acquisition: Dr. Lim has secured significant research funding both internationally and nationally, demonstrating his capability to attract and manage research projects. These grants, such as those for breast cancer research and nanocomposite drug delivery systems, highlight his focus on high-impact research areas.

Graduate Supervision and Mentorship: He has successfully supervised several Ph.D. and Master’s students, which speaks to his role in developing the next generation of researchers. His supervision has led to the completion of innovative theses on topics such as green synthesis of nanoparticles and drug delivery systems.

Professional Recognition and Impact: Dr. Lim has been invited as a keynote speaker and research consultant on numerous occasions, indicating his expertise is well-recognized globally. His visiting fellowships and academic appointments in various countries further emphasize his international standing.

Professional and Community Service: His involvement in professional associations, such as the American Chemical Society and the Malaysian Institute of Chemistry, and his community service, particularly in environmental education and herbal medicine exploration, demonstrate a commitment to applying his expertise beyond academia.

Areas for Improvement

Publication Impact: While Dr. Lim’s research is broad and multidisciplinary, a focus on increasing the impact factor of his publications could strengthen his candidacy. Targeting top-tier journals and increasing citation metrics might further solidify his reputation as a leading researcher.

Research Diversity: Although Dr. Lim has a strong focus on nanotechnology and drug delivery, expanding his research into newer or emerging areas within pharmaceutical sciences could broaden his influence. Engaging in collaborative projects across different disciplines might also bring new perspectives and innovation.

Industry Collaboration: While Dr. Lim has some experience in consulting and contract research, increasing partnerships with the industry could enhance the practical application of his research. Establishing stronger ties with pharmaceutical companies or biotech firms could lead to commercialization opportunities.

Global Presence: Despite his international fellowships and visiting positions, further enhancing his global presence by leading international research consortia or hosting global conferences could elevate his profile further. Participation in global initiatives and publishing in international collaborations could be beneficial.

Education

πŸŽ“ Lim Vuanghao holds a PhD in Pharmaceutical Technology (2010) and an MSc in Pharmacy (2005) from Universiti Sains Malaysia. He also earned a B.Sc. (Hons) in Chemical Sciences from Universiti Putra Malaysia in 2002. Further enhancing his medical expertise, Lim completed a Doctor of Medicine in Acupuncture from the Indian Board of Alternative Medicines and a Diploma in Clinical Acupuncture and Energy Medicine from Xiamen University, China.

Experience

πŸ‘¨β€πŸ« Lim Vuanghao has an extensive academic career, starting as a Research Assistant at the School of Pharmaceutical Sciences, USM, and later as a Lecturer at UCSI University. He has also served as the Head of the Integrative Medicine Cluster at USM, where he played a crucial role in advancing the institute’s research capabilities. Lim is also an active member of various grant evaluation panels and research committees.

Research Interest

πŸ”¬ Lim Vuanghao’s research interests revolve around nanodrug delivery systems, green nano-synthesis, and the application of metabolomics and chemometrics in medical research. His work aims to develop innovative therapeutic strategies, including targeted drug delivery systems for cancer treatment and the use of metabolomics to understand disease mechanisms better.

Awards

πŸ† Lim Vuanghao has received numerous accolades, including an Academic Fellow Scheme (2023) at Universitas Airlangga, Indonesia, and a Senior Visiting Fellowship at Khesar Gyalpo University of Medical Sciences, Bhutan. His contributions to research have also been recognized through Visiting Professorships and Research Scholarships at various international institutions.

Publications Top Notes

πŸ“ Selected Publications:

“Development of Quercetin PEGylated Nanodiamonds for Colon Cancer Inhibition” (2021, Universitas Airlangga). Link to Publication – Cited by 10 articles.

“Medicinal Herb of Clinacanthus Nutans for Nasopharyngeal Cancer: Biological Activity and Mechanism” (2021, Xinxiang Medical University). Link to Publication – Cited by 15 articles.

“Thiolated Alginate-PLGA Nanoparticles for Multi-Drug Resistant Breast Cancer” (2019, USM). Link to Publication – Cited by 20 articles.

Conclusion

Dr. Lim Vuanghao is a strong candidate for the “Best Researcher Award” due to his extensive research contributions, successful mentorship, and professional recognition. His work in nanodrug delivery and metabolomics is highly impactful, and his dedication to both academia and community service underscores his holistic approach to science. While there is room for growth in publication impact, research diversity, and industry collaboration, his current achievements position him as a leading figure in his field. His recognition as a global expert and his ability to secure substantial research funding further support his candidacy for this prestigious award.